Ask AI
ProCE Banner Series

Personalizing Treatment of HER2-Positive Advanced Bladder Cancer: Expert Guidance on the Latest Evidence for HER2-Targeted ADCs

Explore the latest evidence and practical strategies for optimizing care in HER2-positive advanced bladder cancer, with expert guidance on HER2-targeted antibody–drug conjugates (ADCs), molecular testing, treatment sequencing, and adverse event management.

  AMA
Who Should Attend

This activity has been designed to meet the educational needs of oncologists, urologists, pathologists, and other healthcare professionals who care for patients with bladder cancer.

All Events

Personalizing Treatment of HER2-Positive Advanced Bladder Cancer: Expert Guidance on the Latest Evidence for HER2-Targeted ADCs

Upcoming Events

February

27

2026

6:30 PM - 8:00 PM Eastern Time (ET)

In-person

San Francisco Marriott Marquis, 780 Mission Street, San Francisco, California 94103

7:00 PM - 8:00 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners' knowledge, confidence, and competence in the optimal management of patients with HER2-positive advanced bladder cancer.

Target Audience
This activity has been designed to meet the educational needs of oncologists, urologists, pathologists, and other healthcare professionals who care for patients with bladder cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Perform molecular testing and interpretation concordant with expert recommendations to identify patients with advanced bladder cancer who are most likely to benefit from established or emerging HER2-targeted ADCs

  • Evaluate the potential clinical implications of emerging data for novel HER2-targeted ADCs on management of HER2-positive advanced bladder cancer

  • Plan individualized treatment sequences leveraging HER2-targeted ADCs for eligible patients with advanced bladder cancer based on the latest evidence, guidelines, and patient/disease factors

  • Develop strategies to anticipate, monitor, and manage AEs associated with HER2-targeted ADCs in patients with advanced bladder cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/64a7123f4dc56.jpg

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191